Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1985-03-25
1987-04-14
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514826, A61K 31415
Patent
active
046579249
ABSTRACT:
A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.
REFERENCES:
patent: 4432991 (1984-02-01), Dusza et al.
patent: 4447440 (1984-05-01), Busse et al.
W. D. Busse et al, "Nafazatrom (Bay g 6575) an Inhibitor of Cellular Lipoxygenase Activity", Fed. Proc. 47, 1717, No. 8464, (1982).
M. D. Hammond et al, "Nafazatrom: Anti-Asthma Profile in Human Respiratory Tissue In Vitro", Annals of Allergy, XII Int. Congress Allergology and Clin. Immunology, Oct. 20-25, 1985, Washington, D.C.
Busse Wolf-Dieter
Fiedler Volker
Hoffmeister Friedrich
Mardin Mithat
Mayer Dieter
Bayer Aktiengesellschaft
Waddell Frederick E.
LandOfFree
Nafazatrom as a lipoxygenase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nafazatrom as a lipoxygenase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nafazatrom as a lipoxygenase inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1786017